IL87332A - Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them - Google Patents

Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them

Info

Publication number
IL87332A
IL87332A IL87332A IL8733288A IL87332A IL 87332 A IL87332 A IL 87332A IL 87332 A IL87332 A IL 87332A IL 8733288 A IL8733288 A IL 8733288A IL 87332 A IL87332 A IL 87332A
Authority
IL
Israel
Prior art keywords
variants
dna technology
trypsin inhibitor
pharmaceutical compositions
expression vector
Prior art date
Application number
IL87332A
Other languages
English (en)
Other versions
IL87332A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL87332A0 publication Critical patent/IL87332A0/xx
Publication of IL87332A publication Critical patent/IL87332A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL87332A 1987-08-07 1988-08-04 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them IL87332A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8718777A GB2208511A (en) 1987-08-07 1987-08-07 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology

Publications (2)

Publication Number Publication Date
IL87332A0 IL87332A0 (en) 1989-01-31
IL87332A true IL87332A (en) 1993-01-14

Family

ID=10621986

Family Applications (1)

Application Number Title Priority Date Filing Date
IL87332A IL87332A (en) 1987-08-07 1988-08-04 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them

Country Status (11)

Country Link
US (2) US5118668A (es)
EP (1) EP0307592B1 (es)
JP (1) JP2894354B2 (es)
KR (1) KR890003802A (es)
AT (1) ATE173478T1 (es)
AU (1) AU604953B2 (es)
DE (1) DE3856265D1 (es)
ES (1) ES2124685T3 (es)
GB (1) GB2208511A (es)
IL (1) IL87332A (es)
ZA (1) ZA885764B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69033699T2 (de) * 1989-03-06 2001-05-23 The Board Of Regents Of The University Of Texas System, Austin Gegenüber eigenen inhibitoren resistente t-pa mutanten
US5866413A (en) * 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
DE3930522A1 (de) * 1989-09-13 1991-03-21 Bayer Ag Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
US20030223977A1 (en) * 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
DE573603T1 (de) * 1991-03-01 1999-05-06 Dyax Corp., Cambridge, Mass. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
EP0671944A4 (en) * 1992-09-25 1996-07-24 Corvas Int Inc TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR.
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
ES2229236T3 (es) * 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
WO2002078244A1 (en) * 2001-03-27 2002-10-03 Aware, Inc. Receiver transparent q-mode
ATE477020T1 (de) * 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2386310T (pt) * 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
JP4903036B2 (ja) * 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
DE602004031589D1 (de) * 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
ATE398288T1 (de) * 2004-11-15 2008-07-15 Hoffmann La Roche Hoch-durchsatz prion tests
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PL2360258T3 (pl) * 2005-02-18 2015-03-31 Angiochem Inc Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg
US20060247442A1 (en) * 2005-04-29 2006-11-02 Wyeth Process for preparing isatins with control of side-product formation
EP2433653B1 (en) 2005-07-15 2019-06-05 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
EP2069377A4 (en) 2006-09-27 2009-11-11 Univ California METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
PL2164866T3 (pl) 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
US8071555B2 (en) * 2007-10-29 2011-12-06 Helix Biomedix Inc. Protective skin care peptides
BRPI0910557A2 (pt) * 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP2012524030A (ja) 2009-04-20 2012-10-11 アンジオケム インコーポレーテッド Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
JP6037841B2 (ja) * 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
WO2019046801A1 (en) 2017-08-31 2019-03-07 The Regents Of The University Of California MOLECULAR BACTERIOTHERAPY FOR CONTROLLING THE ENZYMATIC ACTIVITY OF THE SKIN

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
SE8604600L (sv) * 1986-10-29 1988-04-30 Nixflu Ab Anordning for att kontrollera kontokort
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
US5032573A (en) * 1987-03-23 1991-07-16 Bayer Aktiengesellschaft Homologs of aprotinin produced from a recombinant host, process, expression vector and recombinant host therefor and pharmaceutical use thereof
DE3724570A1 (de) * 1987-06-27 1989-01-05 Bayer Ag Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DE3930522A1 (de) * 1989-09-13 1991-03-21 Bayer Ag Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben

Also Published As

Publication number Publication date
US5118668A (en) 1992-06-02
AU2058888A (en) 1989-04-20
JPH02480A (ja) 1990-01-05
GB2208511A (en) 1989-04-05
EP0307592A3 (de) 1990-06-06
US5770568A (en) 1998-06-23
ZA885764B (en) 1989-04-26
JP2894354B2 (ja) 1999-05-24
KR890003802A (ko) 1989-04-18
ES2124685T3 (es) 1999-02-16
EP0307592A2 (de) 1989-03-22
EP0307592B1 (de) 1998-11-18
AU604953B2 (en) 1991-01-03
DE3856265D1 (de) 1998-12-24
GB8718777D0 (en) 1987-09-16
ATE173478T1 (de) 1998-12-15
IL87332A0 (en) 1989-01-31

Similar Documents

Publication Publication Date Title
IL87332A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
CA2005502A1 (en) Somatotropin analogs
PT81837A (en) Process for preparing oligopeptides and intermediates therefor
PT85977A (en) Process for the preparation of human apolipoprotein ai and their variant forms by recombinant dna methods
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
AU9026691A (en) New human recombinant gamma interferon
EP0330700A4 (en) Human prourokinase-like polypeptide.
AU3595489A (en) Amblyommin, a new active substance for anticoagulant therapy
HUT75831A (en) Non-splicing variants of gp350/220
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
ATE112290T1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
EP0290029A3 (en) (19-alanine) calcitonin

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees